OrganiGram (OGI) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago.
OrganiGram (OGI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.05 per share a year ago.
Organigram reported solid Q4 earnings, highlighted by achieving a record gross margin and issuing a net revenue guidance implying sustained double-digit organic growth. Quebec's recent vape launch could boost Organigram's Canadian market share, while consumer shift to quality experiences could boost sales of higher-margin liquid diamond vapes. Organigram's expanded capacity and adoption of seed-based cultivation reduce its cost per gram while offering opportunities to increase exports to higher-margin international markets.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Point72 Asset Management LP Point72 Asset Management LP | 10,764 | $18,083.51 | $9,337.77 | -$8,745.74 | -48.36% |
| SE Sima Elimelech Activest Wealth Management | 750 | $1,012.5 | $664.8 | -$347.7 | -34.34% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 252 | $422.7 | $219.77 | -$202.93 | -48.01% |
Michael Byun SageView Advisory Group LLC | 231 | $389 | $198.59 | -$190.41 | -48.95% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $4 | $2.58 | -$1.42 | -35.5% |
| Specialty Retail Industry | Consumer Discretionary Sector | James H. Yamanaka CEO | NASDAQ (NGS) Exchange | 68617J100 CUSIP |
| CA Country | 1,093 Employees | - Last Dividend | 7 Jul 2023 Last Split | - IPO Date |
Organigram Holdings Inc. specializes in the production and sale of cannabis and its derivatives within Canada, focusing on both medicinal and recreational sectors. Since its establishment in 2010, the company has expanded its operations to include a diverse range of cannabis products, catering to a variety of consumer preferences and medical needs. Based in Toronto, Canada, Organigram has successfully positioned itself in the competitive cannabis market through a strategic approach that involves wholesale and direct-to-consumer sales channels. This approach allows Organigram to distribute its products across the nation, ensuring wide availability to both medical retailers and adult-use consumers.
The product lineup of Organigram Holdings Inc. spans across both medical and recreational sectors, offering a broad spectrum of cannabis-derived products. The company's dedication to quality and variety is evident in its comprehensive range of offerings.